03-21-05

DOCKET

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Brenda F. Baker, et al.

Confirmation No.: 5280

Application No.: 10/701,236

Group Art Unit: 1635

Filing Date: November 4, 2003

Examiner: Not Yet Assigned

SUGAR SURROGATE-CONTAINING OLIGOMERIC COMPOUNDS AND

COMPOSITIONS FOR USE IN GENE MODULATION

EXPRESS MAIL LABEL NO: EV325727676US DATE OF DEPOSIT: March 18, 2005

EV325727676US

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

冈 In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

	before the mailing date of a first Office Action after the filing of request for						
	continued examination under § 1.114, no additional fee is required.						
	In accordance with § 1.97(c), this Information Disclosure Statement is being						
	filed after the period set forth in § 1.97(b) above but before the mailing date of						
	either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or						
	before an action that otherwise closes prosecution in the application, therefore:						
	Certification in Accordance with § 1.97(e) is attached; or						
	The fee of \$180.00 as set forth in § 1.17(p) is attached.						
	In accordance with § 1.97(d), this Information Disclosure Statement is being						
	filed after the mailing date of either a Final Action under § 1.113 or a Notice						
	of Allowance under § 1.311 but before, or simultaneously with, the payment						
	of the Issue Fee, therefore included are: Certification in Accordance with §						
	1.97(e); and the submission fee of <u>\$180.00</u> as set forth in § 1.17(p).						
	Copies of reference numbers listed on the attached Form PTO-1449 are						
	enclosed herewith.						
\boxtimes	A copy of reference number 239 on the attached Form PTO 1449 is not						
	required to be submitted pursuant to waiver of 37 CFR § 1.98(a)(2)(i).						
	Copies of references - are not being submitted because						
	they were previously cited by or submitted to the U.S. Patent and						
	Trademark Office in patent application number , filed for						
	which a claim for priority under 35 U.S.C. § 120 has been made in the						
	instant application.						
	elevance of those listed references which are not in the English language is as						
follow	vs:						

DOCKET NO.: ISIS-5207

- 3 -

PATENT

There are no listed references which are not in the English language.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: March 17, 2005

John A. Harrelson, Jr. Registration No. 42,637

WOODCOCK WASHBURN LLP One Liberty Place - 46th Floor Philadelphia, PA 19103

Telephone: (215) 568-3100 Facsimile: (215) 568-3439

© 2005 WW



Application No. Form PTO-1449 Modified Docket No. ISIS-5207 10/701,236 List of Patent and Publications Applicant Cited by Applicant Brenda F. Baker, et al. (Use several sheets if necessary) U.S. Department of Commerce Filing Date Group Patent and Trademark Office November 4, 2003 1635 Confirmation No. 5280 U. S. PATENT DOCUMENTS

Examiner Initial		Document No.	Date	Name	Class	Subclass
*	239	2002/0081736 A1	06/27/02	Conroy, et al.	435	455
					·	
						MIII
	-	L	L			

FOREIGN PATENT DOCUMENTS Examiner

Examiner						Translation	
Initial		Document No.	Date	Country		YES	NO
•		·					

EXAMINER			DATE CONSIDERED				

* Cited on the PCT Written Opinion dated March 7, 2005 (PCT/US03/35146).